Clinical and translational results from the phase 1 portion of the phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers.

CHM 2101 - Chimeric Therap

cyclophosphamide - Generic mfg.

fludarabine IV - Generic mfg.

https://www.asco.org/abstracts-presentations/257773

Jennifer Eads; Jason Litten; Daniel Halperin; Daniel Olson; Meredith Pelster; Xianxin Hua; Amelia Langston; Ardaman Shergill; Rachael Purri; Kimberly Hummel; Stephanie Astrow

Apr 21, 2026